NCI'S EARLY DETECTION RESEARCH NETWORK REPORTS PLATFORM AND CLINICAL REPRODUCIBILITY OF CIPHERGEN'S SELDI PROTEINCHIP

Ciphergen Biosystems announced that the National Cancer Institute's Early Detection Research Network reported completion of the first phase of its development of a proteomics platform using Ciphergen's SELDI ProteinChip System for the detection of prostate cancer.

MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqEYx0bWbmde4CdyWody)